Aclaris Therapeutics (ACRS) Total Liabilities (2014 - 2026)

Aclaris Therapeutics' Total Liabilities history runs 13 years deep, the most recent figure standing at $55.1 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 1.93% year-over-year to $55.1 million in Q1 2026; TTM through Mar 2026 was $55.1 million, a 1.93% increase from a year earlier, with the FY2025 full-year figure at $57.4 million, down 11.42% from the prior year.
• Total Liabilities eased to $55.1 million in Q1 2026 per ACRS's latest filing, from $57.4 million in the prior quarter.
• Across five years, Total Liabilities topped out at $64.8 million in Q4 2024 and bottomed at $27.2 million in Q2 2024.
• The 5-year median for Total Liabilities is $54.0 million (2025), against an average of $50.6 million.
• Across the five-year window, Total Liabilities plunged 51.25% in 2024 and jumped 110.68% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $57.0 million in 2022, then decreased by 29.4% to $40.2 million in 2023, then jumped by 61.02% to $64.8 million in 2024, then retreated by 11.42% to $57.4 million in 2025, then fell by 4.02% to $55.1 million in 2026.
• Per Business Quant, the three latest ACRS Total Liabilities figures stand at $55.1 million (Q1 2026), $57.4 million (Q4 2025), and $55.4 million (Q3 2025).